INBS
BEARISH
$2.46
Live
Intelligent Bio Solutions Inc. · NASDAQ
$2.46
52W Range
$24.9
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 12, 2026
Market cap
$4.92M
P/E
N/A
ROE
-150.2%
Profit margin
N/A
Debt/Equity
0.18
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
95%
The company exhibits severe fundamental distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in financial health. While revenue growth is strong at 47.6% and the balance sheet shows low debt (D/E 0.18), these are overshadowed by an operating margin of -290.89% and a total collapse in share price, which is currently at its 52-week low. The stock is in a clear technical downtrend with a 1-year return of -79.8%, suggesting a lack of investor confidence despite the low Price-to-Book ratio.
Key Strengths
Strong YoY revenue growth of 47.60%
Low Debt-to-Equity ratio (0.18)
Healthy liquidity with a Current Ratio of 2.38
Trading at a significant discount to book value (P/B 0.27)
Improving YoY EPS growth (+97.9%) despite remaining negative
Key Risks
Critical financial health (Piotroski F-Score 1/9)
Extreme operating losses (Operating Margin -290.89%)
Severe price depreciation (down 79.8% over 1 year)
Consistent failure to meet earnings estimates (1/4 beats in last 4 quarters)
Lack of institutional analyst coverage and target price guidance
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
17
Weak
30
40
5
10
0
AI Verdict
High Risk / Speculative
Key drivers: Piotroski F-Score 1/9, Severe operating losses, Technical freefall, Strong revenue growth
Confidence
90%
Value
30/100
Ref P/E N/A, P/B 0.27
Positives
- P/B of 0.27 suggests deep value if assets are tangible
Watchpoints
- No Graham Number available
- Negative earnings make P/E irrelevant
Future
40/100
Ref Growth rates
Positives
- Strong revenue growth (47.6%)
- Improving EPS trend
Watchpoints
- High burn rate
- Unproven path to profitability
Past
5/100
Ref Historical trends
Positives
No standout positives identified.
Watchpoints
- 5Y Change -100%
- 1Y Change -79.8%
- Consistent earnings misses
Health
10/100
Ref Piotroski F-Score
Positives
- Low Debt/Equity
- Good Current Ratio
Watchpoints
- Piotroski F-Score 1/9
- Negative ROE (-150.2%)
Dividend
0/100
Ref Yield 0%
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- No history of payouts
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$2.46
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for INBS and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
INBS
Intelligent Bio Solutions Inc.
Primary
|
-100.0% | -99.3% | -79.8% | -77.0% | -39.7% | -10.6% |
|
CLGN
CollPlant Biotechnologies Ltd.
Peer
|
-97.4% | -95.1% | -85.0% | -83.7% | -43.0% | -33.0% |
|
JAGX
Jaguar Health, Inc.
Peer
|
-100.0% | -100.0% | -92.8% | -82.2% | -34.7% | -7.8% |
|
ISPC
iSpecimen Inc.
Peer
|
-99.9% | -99.5% | -89.9% | -85.3% | -46.7% | -9.9% |
|
BIAF
bioAffinity Technologies, Inc.
Peer
|
-99.5% | -98.4% | -92.9% | -86.5% | +9.8% | -1.5% |
INB
Intelligent Bio Solutions Inc.
Primary
5Y
-100.0%
3Y
-99.3%
1Y
-79.8%
6M
-77.0%
1M
-39.7%
1W
-10.6%
CLG
CollPlant Biotechnologies Ltd.
Peer
5Y
-97.4%
3Y
-95.1%
1Y
-85.0%
6M
-83.7%
1M
-43.0%
1W
-33.0%
JAG
Jaguar Health, Inc.
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-92.8%
6M
-82.2%
1M
-34.7%
1W
-7.8%
ISP
iSpecimen Inc.
Peer
5Y
-99.9%
3Y
-99.5%
1Y
-89.9%
6M
-85.3%
1M
-46.7%
1W
-9.9%
BIA
bioAffinity Technologies, Inc.
Peer
5Y
-99.5%
3Y
-98.4%
1Y
-92.9%
6M
-86.5%
1M
+9.8%
1W
-1.5%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
7.03
PEG Ratio
N/A
P/B Ratio
0.27
P/S Ratio
1.37
EV/Revenue
1.38
EV/EBITDA
-0.5
Market Cap
$4.92M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-290.89%
Gross Margin
46.21%
ROE
-150.2%
ROA
-51.17%
Growth
Revenue and earnings growth rates
Revenue Growth
+47.6%
Earnings Growth
N/A
Q/Q Revenue Growth
+47.62%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.18
Low debt
Current Ratio
2.38
Strong
Quick Ratio
2.17
Excellent
Cash/Share
$0.46
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
51.3%
Op. Margin
-290.9%
Net Margin
-298.6%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
0.61x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
104%
Quarterly Earnings History
EPS performance vs analyst estimates
2024-05-08
$-14.3
-64.4% surprise
2024-02-09
$-20.7
+36.1% surprise
2023-11-08
$-124.8
-62.5% surprise
2023-08-23
$-229.2
-28.2% surprise
Healthcare Sector Comparison
Comparing INBS against 264 companies in the Healthcare sector
(20 bullish, 87 neutral, 157 bearish)
Return on Equity (ROE)
-150.2%
This Stock
vs
-46.09%
Sector Avg
+225.9%
(Excellent)
Debt to Equity
0.18
This Stock
vs
4.1
Sector Avg
-95.7%
(Less Debt)
Revenue Growth
47.6%
This Stock
vs
88.16%
Sector Avg
-46.0%
(Slower)
Current Ratio
2.38
This Stock
vs
3.58
Sector Avg
-33.6%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
INBS
Intelligent Bio Solutions Inc.
|
BEARISH | $4.92M | - | -150.2% | -% | $2.46 | |
|
CLGN
CollPlant Biotechnologies Ltd.
|
BEARISH | $5.18M | - | -117.6% | -% | $0.36 | Compare |
|
JAGX
Jaguar Health, Inc.
|
BEARISH | $4.58M | - | -% | -% | $0.37 | Compare |
|
ISPC
iSpecimen Inc.
|
BEARISH | $3.8M | - | -327.8% | -% | $0.13 | Compare |
|
BIAF
bioAffinity Technologies, Inc.
|
BEARISH | $6.07M | - | -245.2% | -217.5% | $1.35 | Compare |
INBS
Intelligent Bio...
BEARISH
Mkt Cap
$5M
P/E
-
ROE
-150.2%
Price
$2.46
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-18 | SAKIRIS SPIRO KEVIN | Chief Financial Officer | Stock Award | 30,500 | - |
| 2026-03-18 | HURD JONATHAN S | Director | Stock Award | 5,000 | - |
| 2026-03-18 | SIMEONIDIS HARRY | Chief Executive Officer | Stock Award | 30,500 | - |
| 2026-03-18 | BOYAGES STEVEN CONSTANTINE | Director | Stock Award | 5,000 | - |
| 2026-03-18 | ISENBERG JASON | Director | Stock Award | 5,000 | - |
| 2026-03-18 | FRASER NICOLA MARION | Director | Stock Award | 5,000 | - |
SAKIRIS SPIRO KEVIN
Chief Financial Officer
2026-03-18
30,500 shares
HURD JONATHAN S
Director
2026-03-18
5,000 shares
SIMEONIDIS HARRY
Chief Executive Officer
2026-03-18
30,500 shares
BOYAGES STEVEN CONSTANTINE
Director
2026-03-18
5,000 shares
ISENBERG JASON
Director
2026-03-18
5,000 shares
FRASER NICOLA MARION
Director
2026-03-18
5,000 shares
Insider transactions can signal confidence or concerns about company prospects
Past News Coverage
Recent headlines mentioning INBS from our newsroom.
Newest → oldest
No matching news yet.